News
MYNZ
0.8670
+5.98%
0.0489
mRNA Is Promising A Breakthrough In Fighting Cancer
Mainz Biomed is working to revolutionize colorectal cancer diagnostics and prevention. The company's cancer screening test can detect even pre-cancerous polyps thanks to messenger RNA, or mRNA. With the help of mRNA, promising new treatments have emerged for cancer.
Benzinga · 1d ago
Weekly Report: what happened at MYNZ last week (0422-0426)?
Weekly Report · 1d ago
Mainz Biomed Reports Topline Results From Pooled Study Evaluating Novel MRNA Biomarkers And Proprietary AI Algorithm For Integration Into Pivotal FDA PMA Clinical Trial For Next Generation Colorectal Cancer Diagnostic
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90%. Best-in-class sensitivity for advanced adenoma of 82% in 690 subjects. The power to determine advanced cancer lesions in a pre-cancerous stage can change the entire CRC diagnostic field.
Benzinga · 5d ago
Mainz Biomed Announces Upcoming Annual Meeting
TipRanks · 6d ago
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 04/23 12:40
Weekly Report: what happened at MYNZ last week (0415-0419)?
Weekly Report · 04/22 09:53
Mainz Biomed Secures New Funding Agreement
TipRanks · 04/19 11:29
Weekly Report: what happened at MYNZ last week (0408-0412)?
Weekly Report · 04/15 09:49
Cantor Fitzgerald Reiterates Neutral on Mainz Biomed
Benzinga · 04/12 13:58
Analysts’ Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)
TipRanks · 04/12 10:20
MAINZ BIOMED NV <MYNZ.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $2 FROM $3
Reuters · 04/12 10:08
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Johnson & Johnson signed a deal to get Shockwave Medical for $12.5 billion. Bristol Myers Squibb, Merck & Co, Pfizer and Johnson & Johnson are turning to the world's most common causes of death- cancer and heart disease. All four companies are facing the expiration of their patent cliffs. The companies are focusing on cancer and cardiovascular health.
Benzinga · 04/10 14:47
Mainz Biomed B.V. Confronts Escalating Cybersecurity Dangers Threatening Operations and Data Security
TipRanks · 04/10 06:00
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
Mainz Biomed reported earnings per share of -24 cents for the fourth quarter of 2023. The company reported revenue of $214,761. This was 20.46% worse than the analyst estimate of $270,000 for the same period. Mainz biomed also reported results for the third quarter.
Investorplace · 04/10 01:53
Mainz Biomed Reports Full Year 2023 Financial Results
Barchart · 04/09 07:01
Weekly Report: what happened at MYNZ last week (0401-0405)?
Weekly Report · 04/08 09:51
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pfizer and Moderna shares lost about 30% of their respective value over the past year. The struggling pharma companies are promising to turn the tide with their new focus on oncology. Smaller companies like Mainz Biomed N.V. Are already revolutionizing cancer treatment.
Benzinga · 04/02 14:17
Weekly Report: what happened at MYNZ last week (0325-0329)?
Weekly Report · 04/01 09:51
Weekly Report: what happened at MYNZ last week (0318-0322)?
Weekly Report · 03/25 09:52
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
The HALLO DOC! event will take place on March 20, 2024, in Berlin, Germany. Mainz Biomed is a leader in molecular genetics diagnostic solutions for early cancer detection. The event will inform about colorectal cancer, cutting-edge research and new treatment modalities.
Barchart · 03/19 07:01
More
Webull provides a variety of real-time MYNZ stock news. You can receive the latest news about Mainz Biomed NV through multiple platforms. This information may help you make smarter investment decisions.
About MYNZ
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.